Molecure (MOC) Q2 2025 earnings summary

Executive summary

• Focus on R&D of small-molecule drugs for high unmet clinical needs, including oncology and respiratory diseases.

• Report covers the six months ended 30 June 2025, with comparative data for the same period in 2024.

• Business model leads to delayed revenue recognition, with income realized after commercialization/licensing of research results.

Financial highlights

• Total operating revenue for H1 2025: PLN 3.52 million, mainly from government grants.

• Operating loss: PLN 9.13 million (improved from PLN 15.07 million loss in H1 2024).

• Net loss: PLN 8.52 million (vs. PLN 14.60 million loss in H1 2024).

• Cash and equivalents at period end: PLN 32.4 million (up from PLN 17.9 million at 2024 year-end).

• Equity: PLN 94.6 million; total assets: PLN 103.3 million.

Outlook and guidance

• No material uncertainty regarding going concern for at least 12 months from balance sheet date.

• Revenue expected to increase in future periods as projects reach commercialization.